Emilie Mamessier Email & Phone Number | Colorectal cancer (CRC) is one of the most frequent cancers. Despite recent advances in treatment and surgery, the 10-year survival rate is of 50%. As for all cancers, prognosis is largely dependent on the stage at which the cancer is diagnosed and treated. Metastatic spread is the main mortality cause, and in CRC, liver is the main site of metastasis. About 50% of CRC patients develop liver metastasis (synchronous or metachronous liver metastasis, mCCR). Liver resection is the only treatment associated with long-term survival. However, surgery is only possible for 20 to 30% of these patients. For all the other patients, the important challenges remain the early detection and targeting of metastatic malignant cells and the assessment of treatment efficiency. In all these aspects, Circulating Tumor Cells (CTCs) are relevant as they can serve as real-time liquid tumor biopsy. CTCs are believed to detach from the tumor mass, enter the blood circulation and eventually contribute to distant spread in other organs. The study of large cohorts of mCCR patients has proved that CTCs detection and abundance are associated with cancer progression, metastases, poor prognosis and risk of relapse (1-3). In this context, CTCs are extremely interesting to study, as models to understand the metastatic process as biomarkers that might guide treatment decisions and as cells to be targeted to avoid metastasis (4,5). However, CTCs represent a heterogeneous population. Only a low percentage has the true potential to grow into solid metastases, whereas most CTCs may just be unable to survive in periphery. Our objective is to characterize such heterogeneity and identify the CTCs with actual metastatic potential.

Emilie Mamessier

Colorectal cancer (CRC) is one of the most frequent cancers. Despite recent advances in treatment an...
Marseille, Marseille, France

*50 free lookup(s) per month.

No credit card required.

Emilie Mamessier’s Email emilie.mamessier@inserm.fr

Emilie Mamessier’s Phone Numbers

Get EMILIE’s Phone Number (For Free)

Social Media

Emilie Mamessier’s Location Marseille, Marseille, France

Emilie Mamessier’s Current Industry Inserm

Emilie Mamessier’s Prior Industry Harvard Medical School | Ciml | Institute For Child Health Research

Not the Emilie Mamessier you were looking for?

Find accurate emails & phone numbers for over 700M professionals.

Work Experience

Inserm

Team Leader "Predictive Oncology"

2020-09-01 00:00:00 - Present

Harvard Medical School

Associate Research Fellow

2016-11-01 00:00:00 - 2017-11-01 00:00:00

Ciml

CR1

2012-05-01 00:00:00 - 2014-12-01 00:00:00

Institute For Child Health Research

Postdoctoral Research Fellow

2006-01-01 00:00:00 - 2007-02-01 00:00:00

Skills

No Skills Available

Languages

No Languages Available

FAQ About Emilie Mamessier

Emilie Mamessier is located at
Marseille, Marseille, France

Emilie Mamessier is a Colorectal cancer (CRC) is one of the most frequent cancers. Despite recent advances in treatment and surgery, the 10-year survival rate is of 50%. As for all cancers, prognosis is largely dependent on the stage at which the cancer is diagnosed and treated. Metastatic spread is the main mortality cause, and in CRC, liver is the main site of metastasis. About 50% of CRC patients develop liver metastasis (synchronous or metachronous liver metastasis, mCCR). Liver resection is the only treatment associated with long-term survival. However, surgery is only possible for 20 to 30% of these patients. For all the other patients, the important challenges remain the early detection and targeting of metastatic malignant cells and the assessment of treatment efficiency. In all these aspects, Circulating Tumor Cells (CTCs) are relevant as they can serve as real-time liquid tumor biopsy. CTCs are believed to detach from the tumor mass, enter the blood circulation and eventually contribute to distant spread in other organs. The study of large cohorts of mCCR patients has proved that CTCs detection and abundance are associated with cancer progression, metastases, poor prognosis and risk of relapse (1-3). In this context, CTCs are extremely interesting to study, as models to understand the metastatic process as biomarkers that might guide treatment decisions and as cells to be targeted to avoid metastasis (4,5). However, CTCs represent a heterogeneous population. Only a low percentage has the true potential to grow into solid metastases, whereas most CTCs may just be unable to survive in periphery. Our objective is to characterize such heterogeneity and identify the CTCs with actual metastatic potential.